AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8582958 — intervention group
Group type: COMPARATOR
Intervention: 10,000 IU HCG
Number of subjects: 104
Study 1720834 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER, 10 mg once daily for 2 weeks
Number of subjects: 28
Study 1720834 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ), 25 mg once daily for 2 weeks
Number of subjects: 28
Study 6174913 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin eye drops
Number of subjects: 48
Study 6174913 — intervention group
Group type: COMPARATOR
Intervention: Neomycin-polymyxin-gramicidin eye drops
Number of subjects: 48
Study 31692001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl acetate extract
Number of subjects: 43
Study 31692001 — intervention group
Group type: EXPERIMENTAL
Intervention: Petroleum ether extract
Number of subjects: 43
Study 31692001 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of spectral effect relationship
Number of subjects: 43
Study 29084080 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 31
Study 29084080 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 31
Study 25986447 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg daily)
Number of subjects: 253
Study 24867069 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplementation (twice per day for 16 weeks)
Number of subjects: 270
Study 24867069 — intervention group
Group type: COMPARATOR
Intervention: Control drink (twice per day for 16 weeks)
Number of subjects: 270
Study 22942114 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU treatment at 47 J/cm² (141 J/cm² total)
Number of subjects: 0
Study 22942114 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU treatment at 59 J/cm² (177 J/cm² total)
Number of subjects: 0
Study 22942114 — intervention group
Group type: COMPARATOR
Intervention: Sham control (0 J/cm², no energy applied)
Number of subjects: 0
Study 22942114 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU treatment (all energy levels)
Number of subjects: 0
Study 22942114 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 19127427 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1387
Study 19127427 — intervention group
Group type: COMPARATOR
Intervention: CC with two doses rFSH
Number of subjects: 1387
Study 19127427 — intervention group
Group type: COMPARATOR
Intervention: Continuous rFSH
Number of subjects: 1387
Study 17202560 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day)
Number of subjects: 53
Study 17202560 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (54 mg/day)
Number of subjects: 53
Study 17202560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15609471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interleukin (IL)-2 (Proleukin)
Number of subjects: 0
Study 15609471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy with IL-2 and interferon-alfa (biochemotherapy)
Number of subjects: 0
Study 15609471 — intervention group
Group type: COMPARATOR
Intervention: Phase III multicenter studies
Number of subjects: 0
Study 12562068 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) training, 30 minutes daily for 10 treatments
Number of subjects: 50
Study 12562068 — intervention group
Group type: COMPARATOR
Intervention: Traditional training, 30 minutes daily for 10 treatments
Number of subjects: 50
Study 11475729 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatitis decoction
Number of subjects: 561
Study 11475729 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule of Prostatitis decoction
Number of subjects: 561
Study 11475729 — intervention group
Group type: COMPARATOR
Intervention: Qianliekang tablets (Control)
Number of subjects: 561
Study 8580795 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/m2/day etoposide
Number of subjects: 50
Study 8580795 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/m2/day etoposide
Number of subjects: 50
Study 8580795 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/m2/day etoposide (control group)
Number of subjects: 50
Study 2526769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 3 g/day for 9 months
Number of subjects: 26
Study 2526769 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 9 months
Number of subjects: 26
Study 359494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetiedil (100 mg, t.i.d.)
Number of subjects: 40
Study 359494 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg, t.i.d.)
Number of subjects: 40
Study 359494 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline (20 mg, t.i.d.)
Number of subjects: 40
Study 359494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg Lactose, t.i.d.)
Number of subjects: 40
Study 31923778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise program
Number of subjects: 70
Study 31923778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar muscle strengthening exercise program
Number of subjects: 70
Study 31923778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise programs
Number of subjects: 70
Study 31905644 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for eight weeks with a commercially available respiratory muscle trainer (Threshold IMT), 80 inhalations (twice per day, five days per week)
Number of subjects: 16
Study 31905644 — intervention group
Group type: COMPARATOR
Intervention: Regular preseason soccer training including incremental endurance training (IET)
Number of subjects: 16
Study 28346151 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (<7 hours)
Number of subjects: 10086
Study 28346151 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep (>9 hours)
Number of subjects: 10086
Study 28346151 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PA (higher accelerometer counts and ≥20 minutes of accumulated MVPA)
Number of subjects: 10086
Study 26092388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-guideline-recommended supervised physiotherapy exercise sessions (10 sessions) integrated with six (once per week) SIT sessions
Number of subjects: 100
Study 26092388 — intervention group
Group type: COMPARATOR
Intervention: Clinical-guideline-recommended supervised physiotherapy exercise sessions (10) only
Number of subjects: 100
Study 23220080 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide-containing formulations applied twice daily for 28 days
Number of subjects: 20
Study 23220080 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-control treated sites
Number of subjects: 20
Study 21613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous cervical plexus block
Number of subjects: 44
Study 21613278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate cervical plexus block
Number of subjects: 44
Study 19361800 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal support and digital vaginal palpation (DVP) as part of pelvic floor muscle exercise (PFME) training
Number of subjects: 99
Study 19361800 — intervention group
Group type: COMPARATOR
Intervention: PFME with a printed handout instruction
Number of subjects: 99
Study 16780598 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA)
Number of subjects: 1574
Study 16780598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1574
Study 15271098 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose challenge with an interval of 30 min
Number of subjects: 29
Study 15271098 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose challenge with an interval of 60 min
Number of subjects: 29
Study 11216430 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopy (ML)
Number of subjects: 92
Study 11216430 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 92
Study 9264494 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 to 480 mg/d
Number of subjects: 20
Study 9264494 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 to 40 mg/d
Number of subjects: 20
Study 9264494 — intervention group
Group type: COMPARATOR
Intervention: Control group of normotensive subjects
Number of subjects: 20
Study 8283942 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 607
Study 8283942 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 607
Study 3107444 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure ventilator for 3 to 6 hours daily for 3 consecutive days (Group B)
Number of subjects: 15
Study 29978307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 60
Study 29978307 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 60
Study 27320562 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA fentanyl with IV parecoxib 40 mg
Number of subjects: 101
Study 25010921 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation grid (NG)
Number of subjects: 30
Study 25010921 — intervention group
Group type: COMPARATOR
Intervention: Verbal instructions alone (Control)
Number of subjects: 30
Study 22651702 — intervention group
Group type: EXPERIMENTAL
Intervention: True LBBB morphology
Number of subjects: 111
Study 22651702 — intervention group
Group type: COMPARATOR
Intervention: False LBBB morphology
Number of subjects: 111
Study 22651702 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol dose <5 mg
Number of subjects: 111
Study 20646286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural programme
Number of subjects: 125
Study 18586125 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy (PT) training for 12 weeks
Number of subjects: 38
Study 18586125 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy (PT) training + electric muscle stimulation (EMS) for 12 weeks
Number of subjects: 38
Study 18586125 — intervention group
Group type: COMPARATOR
Intervention: Control group (PT only)
Number of subjects: 38
Study 18586125 — intervention group
Group type: COMPARATOR
Intervention: Control group (PT + EMS)
Number of subjects: 38
Study 18586125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PT and PT + EMS)
Number of subjects: 38
Study 16842528 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (n=35)
Number of subjects: 105
Study 16842528 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning (n=70)
Number of subjects: 105
Study 12514398 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 19
Study 12514398 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 19
Study 10971103 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0
Study 10971103 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 10971103 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8843172 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (240 mg orally)
Number of subjects: 17
Study 8843172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1632534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (ketorolac 60 mg IV and bupivacaine 0.5% 30 mL)
Number of subjects: 60
Study 1632534 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.5% 30 mL)
Number of subjects: 60
Study 1632534 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (60 mg)
Number of subjects: 60
Study 6317858 — intervention group
Group type: EXPERIMENTAL
Intervention: VLI contraceptive sponge
Number of subjects: 0
Study 6317858 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm with spermicide
Number of subjects: 0
Study 30753540 — intervention group
Group type: EXPERIMENTAL
Intervention: POIBA intervention (9-session classroom program, 6 weekly physical education sessions, out-of-school physical activity, family workshop)
Number of subjects: 3073
Study 30753540 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (CG)
Number of subjects: 3073
Study 30753540 — intervention group
Group type: EXPERIMENTAL
Intervention: POIBA intervention
Number of subjects: 3073
Study 29874959 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed accounts (high detail)
Number of subjects: 0
Study 29874959 — intervention group
Group type: COMPARATOR
Intervention: Vague accounts (low detail)
Number of subjects: 0
Study 29874959 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional accounts
Number of subjects: 0
Study 29874959 — intervention group
Group type: COMPARATOR
Intervention: Non-emotional accounts
Number of subjects: 0
Study 29874959 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence measures
Number of subjects: 0
Study 29874959 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability measures
Number of subjects: 0
Study 29874959 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality measures
Number of subjects: 0
Study 29874959 — intervention group
Group type: EXPERIMENTAL
Intervention: Political orientation measures
Number of subjects: 0
Study 27048410 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy for 8 weeks
Number of subjects: 76
Study 27048410 — intervention group
Group type: COMPARATOR
Intervention: Medication group (budesonide nasal spray with cetirizine tablets for 8 weeks)
Number of subjects: 76
Study 25282707 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ intervals analysis
Number of subjects: 62
Study 25282707 — intervention group
Group type: EXPERIMENTAL
Intervention: CAFW analysis
Number of subjects: 62
Study 25282707 — intervention group
Group type: EXPERIMENTAL
Intervention: RPI for paroxysmal AF cases
Number of subjects: 62
Study 22704059 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a parental history of depression
Number of subjects: 50
Study 22704059 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study 20682573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 220
Study 20682573 — intervention group
Group type: COMPARATOR
Intervention: 1% plain subcutaneous lidocaine
Number of subjects: 220
Study 17717933 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi Drop Pill
Number of subjects: 0
Study 15640488 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (6 g green tea solids)
Number of subjects: 17
Study 15640488 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (6 g black tea solids)
Number of subjects: 17
Study 15640488 — intervention group
Group type: COMPARATOR
Intervention: Control (360 mg caffeine)
Number of subjects: 17
Study 12360170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (5 sessions of 45 minutes per week for 2 months)
Number of subjects: 24
Study 12360170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 24
Study 10418844 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response
Number of subjects: 28
Study 10418844 — intervention group
Group type: COMPARATOR
Intervention: Tone-evoked P300 response
Number of subjects: 28
Study 10418844 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response in mild TBI
Number of subjects: 28
Study 10418844 — intervention group
Group type: COMPARATOR
Intervention: Tone-evoked P300 response in mild TBI
Number of subjects: 28
Study 10418844 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response in severe TBI
Number of subjects: 28
Study 10418844 — intervention group
Group type: COMPARATOR
Intervention: Tone-evoked P300 response in severe TBI
Number of subjects: 28
Study 10418844 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-evoked P300 response in moderate TBI
Number of subjects: 28
Study 10418844 — intervention group
Group type: COMPARATOR
Intervention: Tone-evoked P300 response in moderate TBI
Number of subjects: 28
Study 7560667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate (100 mg administered intravenously)
Number of subjects: 53
Study 7560667 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (oral challenge)
Number of subjects: 53
Study 7560667 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 53
Study 2393271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (mean, 178.6 mg/h)
Number of subjects: 29
Study 2393271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (mean, 330.0 mg/h)
Number of subjects: 29
Study 2393271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 29
Study 2393271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 29
Study 7015262 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Number of subjects: 80
Study 7015262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Number of subjects: 80
Study 7015262 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term therapy (one or four days of antibiotics)
Number of subjects: 80
Study 7015262 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (ten-day regimen)
Number of subjects: 80
Study 7015262 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term therapy (all children in both studies)
Number of subjects: 80
Study 7015262 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (all children in both studies)
Number of subjects: 80
Study 30625184 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy dog exposure (15 min)
Number of subjects: 86
Study 30625184 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 86
Study 29995456 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 days of bed rest
Number of subjects: 12
Study 29995456 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream regulator analysis of MEF2 family
Number of subjects: 12
Study 29995456 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroRNA expression analysis
Number of subjects: 12
Study 27687468 — intervention group
Group type: EXPERIMENTAL
Intervention: nerve stimulator-guided pudendal nerve block (PNB)
Number of subjects: 57
Study 27687468 — intervention group
Group type: COMPARATOR
Intervention: general anesthesia (GA)
Number of subjects: 57
Study 24908551 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir (switch group)
Number of subjects: 433
Study 24908551 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor with emtricitabine and tenofovir (no-switch group)
Number of subjects: 433
Study 20977611 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants with immediate loading (group A)
Number of subjects: 60
Study 20977611 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading after 3 months (group B)
Number of subjects: 60
Study 19441871 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir DF 200 mg/300 mg once daily plus lopinavir/ritonavir
Number of subjects: 0
Study 19441871 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir DF 200 mg/300 mg once daily
Number of subjects: 0
Study 19441871 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir DF in combination with various boosted PIs
Number of subjects: 0
Study 17497471 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly (n = 47)
Number of subjects: 127
Study 17497471 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly (n = 44)
Number of subjects: 127
Study 17497471 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg per day (n = 36)
Number of subjects: 127
Study 15515441 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training program for nursing assistants
Number of subjects: 0
Study 11570731 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lifting task
Number of subjects: 32
Study 11570731 — intervention group
Group type: COMPARATOR
Intervention: Lying on the back for 8 hours
Number of subjects: 32
Study 11246837 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group (group E) with antihypertensive drug treatment and patient education
Number of subjects: 169
Study 11246837 — intervention group
Group type: COMPARATOR
Intervention: Routine group (group R) with antihypertensive drug treatment alone
Number of subjects: 169
Study 7843814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g administered intravenously within 1 h before surgery and a second dose 3-4 days postoperatively.
Number of subjects: 101
Study 7843814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis).
Number of subjects: 101
Study 7843814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone treatment.
Number of subjects: 101
Study 3322826 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 4081
Study 3322826 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 4081
Study 30035580 — intervention group
Group type: EXPERIMENTAL
Intervention: MCQ/MCQ
Number of subjects: 84
Study 30035580 — intervention group
Group type: EXPERIMENTAL
Intervention: MCQ/MCQ-A
Number of subjects: 84
Study 28628810 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration (starting dose 2μg/kg/d)
Number of subjects: 15
Study 28628810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25637651 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed condition (additional irrelevant colour cue shown during presentation)
Number of subjects: 24
Study 25637651 — intervention group
Group type: COMPARATOR
Intervention: Unexposed condition (no additional colour cue)
Number of subjects: 24
Study 25637651 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed patients (additional irrelevant colour cue shown during presentation)
Number of subjects: 24
Study 25637651 — intervention group
Group type: COMPARATOR
Intervention: Unexposed patients (no additional colour cue)
Number of subjects: 24